Organization | Suzhou Hospital of Traditional Chinese Medicine

Suzhou Hospital of Traditional Chinese Medicine Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial

2012

NCT01274936

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Suzhou Hospital of Traditional Chinese Medicine

Active Ingredients

Drugs in Phase 3 Trials (2)

qi-zheng-xiao-tong (1 trial)

tong-luo-qu-tong (1 trial)

Drugs in Phase 2 Trials (9)

autologous cd19/cd22 chimeric antigen receptor t-cells (1 trial)

autologous hematopoietic stem cells (1 trial)

azacitidine (vidaza) (4 trials)

chidamide (1 trial)

cladribine (leustatin) (2 trials)

cytarabine (cytosar-u) (2 trials)

inotuzumab ozogamicin (besponsa) (1 trial)

qishen (1 trial)

venetoclax (venclexta) (6 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Musculoskeletal Diseases (Phase 3)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Radiculopathy (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 10
# of Trial APIs: 11